Skip to main content
Clinical Trials/NL-OMON29295
NL-OMON29295
Recruiting
Not Applicable

Delirium treatment at the geriatric ward (DELTa G)Treatment of delirium: rivastigmine or haloperidol as primary treatment for delirium in delirious patients on a geriatric ward.A randomized placebo-controlled study.

trial medication is sponsored by Novartis0 sites100 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
trial medication is sponsored by Novartis
Enrollment
100
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

/A

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
trial medication is sponsored by Novartis

Eligibility Criteria

Inclusion Criteria

  • Patients on a geriatric ward and delirium.

Exclusion Criteria

  • 1\. Already use of rivastigmine/donepezil or galantamine;
  • 2\. Parkinson(ism).

Outcomes

Primary Outcomes

Not specified

Similar Trials